← All trials
NCT05302388
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 28, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Jun 30, 2024
- First posted
- Mar 31, 2022
- Last posted
- Apr 8, 2022
- Enrollment
- 45
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China National Biotec Group Co., LtdLead sponsor
- China National Biotec Group Co., LtdStudy director
- Bengbu Medical CollegeCollaborator
- Bengbu Medical CollegeOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.